Amphastar Pharmaceuticals, Inc. (AMPH) Financials
AMPH Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 1.5 billion | 873.5 million |
| 2023-09-30 | 1.5 billion | 949.5 million |
| 2023-06-30 | 1.4 billion | 789.0 million |
| 2023-03-31 | 773.7 million | 225.1 million |
AMPH Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | 14.4 million | 4.6 million |
| 2023-09-30 | 54.1 million | 4.6 million |
| 2023-06-30 | 45.9 million | 4.9 million |
| 2023-03-31 | 30.9 million | 6.1 million |
AMPH Net Income
Graph available only for supporters. Become a supporter to see it.
| Date | Net Income |
|---|---|
| 2023-12-31 | 36.2 million |
| 2023-09-30 | 49.2 million |
| 2023-06-30 | 26.1 million |
| 2023-03-31 | 26.0 million |
AMPH Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 259.2 million | - | 33.6 million |
| 2023-09-30 | 299.9 million | - | 33.9 million |
| 2023-06-30 | 163.1 million | 488.3 million | 27.5 million |
| 2023-03-31 | 192.9 million | 72.9 million | 27.0 million |
AMPH Shares Outstanding
AMPH Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 9.4 million | 17.8 million | 13.1 million | 8.6 million |
| 2023-09-30 | 10.2 million | 16.7 million | 12.7 million | 6.4 million |
| 2023-06-30 | 9.1 million | 16.8 million | 12.3 million | 6.7 million |
| 2023-03-31 | 9.5 million | 19.8 million | 13.5 million | 7.1 million |
AMPH Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 178.1 million | 84.5 million |
| 2023-09-30 | 180.6 million | 72.2 million |
| 2023-06-30 | 145.7 million | 73.0 million |
| 2023-03-31 | 140.0 million | 66.2 million |
AMPH
Price: $42.08
52 week price:
Payout Ratio Range:
Earnings Per Share: 2.60 USD
P/E Ratio: 21.72
Exchange: NMS
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 105125
Ebitda: 2.1 millionMarket Capitalization: 2.0 billion